The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. CHICAGO / Dec 03, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS)... Read More

Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are two underdiagnosed, potentially fatal forms of heart disease that standard diagnostic testing routinely fails to detect CHICAGO / Nov 05, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc . (Nasdaq: CDIO), an AI-powered Precision Cardiovascular Medicine company, today announced that the... Read More

A customized program for YMCA of East Tennessee members will include educational series “Wisdom Wednesdays,” and access to Cardio Diagnostics’ AI-powered cardiovascular testing at discounted rates from home or during the Heart Health Fair KNOXVILLE, Tenn. & CHICAGO / Oct 28, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that... Read More

Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care Practices CHICAGO / Oct 21, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the United States. This expansion demonstrates the continued... Read More

Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO / Jul 22, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS), through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and... Read More

AGEPHA Pharma will supply LODOCO® (low-dose colchicine) for a Cardio Diagnostics-sponsored clinical study to explore the use of Cardio Diagnostics’ PrecisionCHD™ test to identify patients with inflammation-driven coronary heart disease (CHD) CHICAGO / Jul 08, 2025 / Business Wire / Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO), a precision cardiovascular medicine company with a pioneering technology at the intersection of... Read More

CHICAGO / Jun 10, 2025 / Business Wire / Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s intellectual property portfolio. The patent, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,” (Japanese... Read More

CHICAGO / May 29, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a pioneer in AI-powered precision cardiovascular medicine, today announced that on May 28, 2025, it received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance... Read More

CHICAGO / May 20, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a pioneer in AI-powered precision cardiovascular medicine, today announced the continued expansion of its reach with a new cohort of healthcare practices across the United States now offering its innovative clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™. This group of adopters spans a wide range of care models - from concierge... Read More

CHICAGO / May 08, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (“Cardio” or the “Company”) (NASDAQ: CDIO), today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025. The reverse stock split will take effect at 11:59 pm Eastern Time on May 12, 2025, and the Company’s common stock will open for trading on The Nasdaq Capital Market on May 13, 2025 on a... Read More

CHICAGO / Mar 26, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced its participation in the American College of Cardiology’s 74th Annual Scientific Session & Expo (ACC.25) , taking place March 29-31, 2025, at McCormick Place in Chicago, IL. Cardio Diagnostics will be exhibiting at Booth #2033, showcasing its growing portfolio of... Read More

CHICAGO / Feb 04, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced that the Company has partnered with seven new provider organizations. This expansion highlights the growing adoption of the Company’s cutting-edge blood tests, Epi+Gen CHD™ and PrecisionCHD™, designed to transform the prevention, detection, and management of... Read More

CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO / Dec 16, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare & Medicaid Services (CMS). Following the... Read More

CHICAGO / Nov 12, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, today announced it will sponsor and exhibit at the Florida Association of ACOs (FLAACOs) 2024 Annual Fall Conference, taking place in Orlando, FL, from November 20-22, 2024. The conference, hosted at the JW Marriott Orlando Bonnet Creek, brings together healthcare leaders and... Read More

Preliminary CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO / Oct 01, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from the Centers for Medicare & Medicaid Services... Read More

CHICAGO / Jul 29, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI . This new site emphasizes the Company's AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death globally. This... Read More

CHICAGO / Jun 27, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood test, Epi+Gen CHD is now available at Family Medicine Specialists’ (FMS) retail clinical location at the Meijer Supercenter in McHenry, Illinois. Expanding Access in the Midwest Meijer, a privately owned and family-operated... Read More

CHICAGO / Jun 25, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum, taking place in Chicago, IL, from June 27-28, 2024. The Forum attracts senior executives from various healthcare... Read More

CHICAGO / Jun 10, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-driven precision cardiovascular medicine, today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit, achieving compliance with the leading industry standards for customer data security. This milestone underscores the Company’s unwavering commitment to the highest data security... Read More

Company to recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the Molecular Diagnostic Services (MolDx) program. CHICAGO / May 21, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, today announced its participation in the Clinical Laboratory Fee Schedule (CLFS) Annual Meeting on June 25, 2024. At this meeting... Read More

CHICAGO / May 13, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood tests, Epi+Gen CHD and PrecisionCHD, are now available at Family Medicine Specialists’ (FMS) newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois. FMS is a leading primary care and risk-bearing provider... Read More

The Peer-Reviewed Publication Demonstrates the Potential Economic Benefits of the PrecisionCHD™ Test for the Detection and Management of Coronary Heart Disease, which is One of the Largest Cost Centers for Public and Private Payers. CHICAGO / Apr 29, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in the next generation of precision cardiovascular medicine technologies that combine... Read More

Exponential Health, an innovative concierge medicine practice in Michigan, adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests, marking a new era in personalized and preventive cardiac care. CHICAGO / Apr 09, 2024 / Business Wire / In a significant stride towards transforming cardiovascular healthcare in concierge specialty and primary care offices, Exponential Health , an innovative concierge medical practice led... Read More

CHICAGO / Apr 04, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc . (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre , an innovative digital health technology platform which revolutionizes how patients access healthcare and serves as a true health companion for every stage from birth to the golden years with a robust care navigation, wellness, and... Read More

CHICAGO / Mar 14, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc . (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announces that the Company will showcase its groundbreaking HeartRisk TM and Actionable Clinical Intelligence TM platforms at the American College of Cardiology’s 73rd Annual Scientific Session (ACC.24) , taking place in Atlanta, GA, from April 6-8, 2024. Cardio Diagnostics'... Read More

Company Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind Technology CHICAGO / Mar 05, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces that the U.S. Patent and Trademark Office has issued a notice of allowance to University of Iowa Research Foundation ("UIRF") for U.S. Application No. 17,857,723 titled... Read More

Transformative Cardiovascular Risk Management Solutions Extend Beyond Traditional Sectors to Include Federal and State Correctional Facilities, Broker and Benefits Organizations, and Risk Bearing Providers. CHICAGO / Feb 15, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announced today the nationwide rollout and a significant expansion of its... Read More

Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a retail healthcare setting on a walk-in basis. CHICAGO / Feb 07, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, today announced that the Company’s AI-driven epigenetic-genetic blood tests, Epi+Gen CHD and... Read More

resTOR to be the first longevity clinic nationwide to offer the Company's blood-based epigenetic-genetic cardiovascular disease tests CHICAGO / Feb 05, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces that Houston-based resTOR Longevity Clinic will integrate Cardio Diagnostics' solutions into its battery of tests for new patients in its... Read More

Cardio Diagnostics’ AI-driven coronary heart disease (CHD) tests have taken another promising step in their evolution. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, has been assigned two dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA); 0440U for the company’s AI-driven CHD detection test, PrecisionCHD, and 0439U for the... Read More

CHICAGO / Jan 24, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the... Read More

The Company’s global patent portfolio includes granted patents in the United States, Europe, India, Australia, China and Hong Kong, and numerous pending patents worldwide CHICAGO / Jan 08, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc . (Nasdaq: CDIO), a pioneering AI-driven precision cardiovascular medicine company, today announced that India’s Patent Office has granted a patent to the University of Iowa Research... Read More

HeartRisk™ Empowers Employers Who Adopt Cardio Diagnostics’ Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and Mitigate Business Risks CHICAGO / Jan 04, 2024 / Business Wire / Please replace the release with the following corrected version due to multiple revisions. The updated release reads: CARDIO DIAGNOSTICS HOLDINGS, INC. UNVEILS GROUNDBREAKING EMPLOYER CARDIOVASCULAR DISEASE RISK INTELLIGENCE... Read More

HeartRisk™ Empowers Employers Who Adopt Cardio Diagnostics’ Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and Mitigate Business Risks CHICAGO / Jan 04, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced that the Company’s new HeartRisk proprietary data intelligence platform will be made available to... Read More

This is the second CPT PLA code the American Medical Association (AMA) granted for the Company’s AI-powered coronary heart disease tests. This significant milestone enables the acceleration of reimbursement for the Epi+Gen CHD test from federal and private payers, while increasing access to this precision cardiovascular medicine test. CHICAGO / Jan 03, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc . (Nasdaq: CDIO),... Read More

Obtaining a CPT PLA code marks a key milestone in securing reimbursement from federal and private payers for, and expanding access to the innovative PrecisionCHD test powered by AI and epigenetics CHICAGO / Jan 02, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced that the American Medical Association (AMA) has assigned a dedicated... Read More

CHICAGO / Dec 21, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at... Read More

CHICAGO / Dec 06, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced that on December 5, 2023, it received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company... Read More

The roundtable will bring together healthcare stakeholders to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space CHICAGO / Dec 04, 2023 / Business Wire / Headline of release should read: Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42 nd Annual J.P. Morgan Healthcare Conference (instead of Cardio Diagnostics... Read More

The roundtable will bring together healthcare stakeholders to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space CHICAGO / Dec 04, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the company’s management will be attending the 42nd... Read More

CPT codes are critical to receiving reimbursement from federal and private payers CHICAGO / Nov 28, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT... Read More

CHICAGO / Nov 20, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA) , an official journal of the American Heart Association. This study, conducted in collaboration with Intermountain Healthcare and... Read More

CHICAGO / Nov 07, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a leading Illinois primary care provider with eight locations and tens of thousands of patients across Illinois, today announced that FMS is implementing Cardio Diagnostics’ solutions to identify patients at risk... Read More

Contract awarded for products that bring improvement to healthcare industry. CHICAGO / Oct 31, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced its AI-driven molecular heart disease tests, which identify objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have... Read More

CHICAGO / Oct 17, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced a significant move to transform global cardiovascular health, by entering into a Supply and Distribution Agreement with one of India’s premier organizations, Aimil Ltd . Aimil, a company at the forefront of the instrumentation industry... Read More

CHICAGO / Oct 12, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced the launch of the Company’s new integrated facility in Iowa City, Iowa. This facility will house Cardio Diagnostics' new research laboratory, high-complexity Clinical Laboratory Improvement Amendments (CLIA) laboratory, and fulfillment... Read More

CHICAGO / Sep 20, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that researchers from Cardio Diagnostics and Dr. Damon Broyles published a peer-reviewed article outlining scalable pathways that leverage precision epigenetics to revolutionize coronary heart disease (CHD) care globally, a leading cause... Read More

CHICAGO / Sep 07, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced a strategic collaboration with Truckers Health Network, an organization providing health and wellness options to truckers and trucking companies. Truckers are disproportionately affected by heart disease and this partnership marks a... Read More

CHICAGO / Sep 06, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced its AI-driven Epi+Gen CHD and PrecisionCHD tests will be leveraged in a research study led by Dr. Vishal Gupta, a cardiologist and the head of the Heart Attack Prevention Clinic at Ascension Borgess. As the burden of cardiovascular... Read More

CHICAGO / Sep 05, 2023 / Business Wire / Cardio D iagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that Meesha Dogan, Ph.D., CEO of Cardio Diagnostics, will present at the following investor conferences: H.C. Wainwright 25th Annual Global Investment Conference Date: September 11-13, 2023 CDIO Presentation: September 13, 2023 Venue:... Read More

CHICAGO / Aug 18, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced the successful completion of an employer-sponsored heart disease fair in Kansas, United States. FRSTeam of East Kansas and West Missouri, leaders in restoring and cleaning textiles, electronics, and contents in residential and commercial... Read More

CHICAGO / Aug 02, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that Australia’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Australian Patent Application No. 2017277666, titled “Compositions and Methods for Detecting Predisposition to... Read More

CHICAGO / Jul 06, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced a partnership with Austin, Texas-based concierge, and executive health practice, RiverRock Medical. This partnership establishes RiverRock Medical as the first service provider in Austin, Texas, to incorporate Epi+Gen CHD and PrecisionCHD,... Read More

Coronary Heart Disease Detection Test Merges Epigenetic and Genetic Biomarkers with Artificial Intelligence, Offering Remote and Scalable Deployment Capabilities Across the Nation CHICAGO / Jun 21, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer in AI-driven precision cardiovascular medicine tests, today announces the nationwide launch of PrecisionCHD™. This groundbreaking test marks a... Read More

The study represents a significant breakthrough in understanding the potential for reversing and measuring epigenetic changes associated with coronary heart disease after therapeutic intervention CHICAGO / Jun 13, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc ( Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced the publication of groundbreaking research in... Read More

CHICAGO / May 16, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, announced the introduction of the Actionable Clinical Intelligence TM (ACI) platform to expand the information available to clinicians prescribing the Epi+Gen CHD and PrecisionCHD laboratory developed tests (LDTs). ACI offers new data-driven insights into the... Read More

CHICAGO / May 10, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced a partnership with Connect Clinic to help MidWest/South Central self-insured employers build access to heart disease initiatives. These states lack ready access to precision heart disease technologies needed to tackle cardiovascular disease at scale while also having a very... Read More

This research-use-only offering supports the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases. CHICAGO / May 04, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced the availability of its CardioInnovate360 TM research-use-only (RUO) solution for biopharmaceutical... Read More

List recognizes most innovative and impactful digital health solutions that have the potential to make a significant impact in the future. CHICAGO / Apr 26, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced its PrecisionCHD™ test received Juniper Research’s Future Digital Award for the “Best Digital Diagnostics Solution.” Juniper Research’s... Read More

CHICAGO / Apr 12, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is participating and exhibiting at the 22 nd Annual Association of Home Office Underwriters (AHOU) Conference, a premier event for the life insurance underwriting industry. The conference will take place from April 16-19, 2023, at The Diplomat Beach Resort in Hollywood, Florida. Cardio Diagnostics will be... Read More

CHICAGO / Apr 05, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced a strategic engagement with Lifespan.io , a leading nonprofit advocacy foundation and online platform focusing on the extension of healthy human lifespan through research and education. This engagement seeks to enhance public awareness and... Read More

CHICAGO / Mar 29, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 13th Annual Meeting. The conference is taking place next week, April 3-6, 2023, at the Hyatt Regency Hotel in Chicago. As part of Cardio Diagnostics’ sponsorship, the Company is further introducing their recently launched test, PrecisionCHD, at booth #300. Becker’s Hospital... Read More

CHICAGO / Mar 08, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (the “Company”) (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that it has entered into a securities purchase agreement (“Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”), under which the Company agreed to sell... Read More

CHICAGO / Mar 08, 2023 / Business Wire / Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced Dr. Damon Broyles, MD, the VP of Clinical Innovation at Mercy Technology Services (MTS), the technical support arm of Mercy Healthcare, has joined Cardio Diagnostics as a strategic advisor. Strategic advisors at Cardio Diagnostics are pivotal... Read More

CHICAGO / Mar 02, 2023 / Business Wire / Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Chinese Patent Application No. 201780049286.4, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular... Read More

CHICAGO / Feb 22, 2023 / Business Wire / Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that its newest coronary heart disease test, PrecisionCHD ™ , will be presented at the American College of Cardiology’s 72nd Annual Scientific Session (ACC.23), taking place in New Orleans, LA, from March 4-6, 2023. PrecisionCHD, the company’s... Read More

Leading Medical Practice in Idaho Will be the First Functional Medicine Clinic to Offer the Epi+Gen CHD Precision Cardiovascular Test Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Healing Sanctuary Clinic, a leading medical practice serving health-forward consumers in Idaho, today announced the availability of Cardio Diagnostics’ Epi+Gen CHD test in Idaho. As a... Read More

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a precision cardiovascular diagnostics company, announced today that it will attend the JP Morgan Healthcare Conference, January 9-12, 2023. The JP Morgan Healthcare Conference, which will be held in San Francisco, is an annual event that brings together the leaders and innovators of the healthcare industry. The event is a gathering place for the healthcare industry’s leaders... Read More

Leading concierge medicine practice in Houston will be the first concierge medicine to offer the Epi+Gen CHD precision cardiovascular disease test to executives in Houston, Texas. Cardio Diagnostics Holdings Inc ( Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Houston Concierge Medicine, a leading medical practice serving executives and health-forward consumers in Houston, today announced the use... Read More